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Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can prevent
HIV-1 infection in humanized mice and macaques when passively transferred. New single-cell-
based methods have uncovered many broad and potent donor-derived antibodies, and structural
studies have revealed the molecular bases for their activities. The new data suggest why such
antibodies are difficult to elicit and inform HIV-1 vaccine development efforts. In addition to pro-
tecting against infection, the newly identified antibodies can suppress active infections in mice
and macaques, suggesting they could be valuable additions to anti-HIV-1 therapies and to strate-
gies to eradicate HIV-1 infection.HIV-1 Env as an Escape Artist
The HIV-1 infection cycle begins with host cell recognition and
entry mediated by the HIV-1 envelope spike (Env) on the
surface of the virion (Figure 1). Each Env is composed of a
trimer of identical gp160 protein subunits that are cleaved
posttranslationally to yield two associated glycoproteins,
gp120 and gp41: gp120 carries the recognition sites for the
host receptor (CD4) and coreceptor (primarily CCR5 and
CXCR4), and gp41 mediates fusion between the virus and host
cell membranes.
During acute infection with HIV-1, serum viral loads peak
approximately 3 weeks after transmission and then fall 1–2
logs to a set point determined by the host immune system
(Cohen et al., 2011; Daar et al., 1991). T cells are primarily
responsible for this partial control of viral replication in the early
phases of HIV-1 infection (Goonetilleke et al., 2009; Koup et al.,
1994). In rare individuals who carry specific HLA alleles such as
HLA-B*5701, T cell responses can even reduce viremia to
undetectable levels for prolonged periods of time (Migueles
et al., 2000).
In contrast, antibodies appear not to contribute significantly to
the control of HIV-1 during natural infection. Anti-Env antibodies
can be detected several weeks after infection. The initial
antibody response is directed against gp41 and has little effect
on viral dynamics (Cooper et al., 1987; McMichael et al., 2010;
Tomaras et al., 2008). Gp120-directed antibodies with auto-
logous neutralizing activity develop 4–14 weeks after infection
and exert considerable selective pressure that shapes the emer-
gence of Env variants (Bar et al., 2012; Gray et al., 2007; Mikell
et al., 2011; Wei et al., 2003). However, HIV-1 mutates at a suffi-
ciently high rate and produces enough diversity in the viral
population that the viral swarm in any infected person appears
to contain resistant variants to any developing antibody (Weiet al., 2003). This extraordinary potential for HIV-1 escape from
antibodies parallels its ability to escape from antiretroviral drugs
(Davey et al., 1993; Goldberg et al., 2012; Richman et al., 1994).
The result is a continuing race between newly developing
antibodies and the rapidly mutating virus, which ultimately leads
a small percentage of HIV-1-infected individuals to produce
antibodies that can neutralize a broad range of different viral
strains (Doria-Rose et al., 2010; Mikell et al., 2011; Moore
et al., 2012; Simek et al., 2009).
Structural and biophysical studies have revealed a number of
features of Env that enable HIV-1 to evade the human antibody
response. Remarkably common in the set of resistant variants
are those that add or remove potential N-linked glycosylation
sites (PNGS) (Sagar et al., 2006; van Gils et al., 2011; Wei
et al., 2003). The many glycans decorating the surface of Env
form a ‘‘glycan shield’’ that reduces access to protein epitopes.
These glycans have the same chemical structures found on host
glycoproteins, and individually they are therefore indistinguish-
able from the host, impeding development of uniquely glycan-
specific anti-HIV antibodies.
Immune evasion also results from conformational masking of
key conserved functional sites on HIV-1 Env (Kwong et al.,
2002). For example, the coreceptor binding site is not fully
exposed until after the CD4-binding site on gp120 is engaged
by CD4. Similarly the fusion machinery in the membrane-
proximal external region (MPER) of gp41 is not exposed until
after the coreceptor binding site is occupied and the virus begins
the fusion process (Frey et al., 2008). Thus, conformational
masking diminishes the effects of antibodies that target these
two relatively conserved regions by restricting access.
Consistent with an important role for glycosylation and confor-
mational masking in HIV-1 escape from neutralizing antibodies,
HIV-2, which has less glycosylation in the gp120 V4 loopCell 156, February 13, 2014 ª2014 Elsevier Inc. 633
Figure 1. Epitopes of Broadly Neutralizing
Antibodies on HIV-1 Env
Electron microscopy structure of Env trimer (Liu
et al., 2008) with approximate locations of epi-
topes highlighted on surface representation (each
epitope is shown once per trimer): CD4-binding
site Ab epitope (red), V3 loop/Asn332 Ab epitope
(glycan attached to Asn332 as space filling model)
(blue), V1/V2 loop/Asn160 Ab epitope (glycan
attached to Asn160 as space filling model) (green),
MPER epitope (yellow). N-linked glycans are
shown as gray sticks and were added to all po-
tential N-linked glycosylation sites present in the
coordinates for BG505 SOSIP Env (PDB 4NCO)
using the GlyProt server.and less conformational masking than HIV-1, elicits broadly
neutralizing antibodies (bNAbs) far more frequently than HIV-1
(de Silva et al., 2012; Kong et al., 2012; Ozkaya Sahin et al.,
2012).
In addition to the challenges posed by the glycan shield and
conformational masking, the potency of anti-Env antibodies is
reduced by their limited ability to bind with avidity to the relatively
small number of spikes on the viral surface (Klein and Bjorkman,
2010; Mouquet et al., 2010). While most bacterial and viral
pathogens present dense arrays of antigens, HIV-1 displays
only 14 Env trimers per virion (Chertova et al., 2002; Liu et al.,
2008; Zhu et al., 2006). The paucity of surface spikes makes it
difficult to achieve bivalent antibody binding to two adjacent
spikes because the average distance between them usually
exceeds the distance that can be spanned by the two Fab
arms of an antibody. Furthermore, the Env trimer geometry
generally prevents bivalent antibody binding to epitopes on
adjacent monomers in the same trimer (Figure 1). These factors
suggest that anti-HIV-1 antibodies only rarely bind bivalently, an
idea supported by the relatively small differences in potency
between the IgG and Fab forms of the antibodies that have
been tested (Klein and Bjorkman, 2010).
A major advance in understanding the quaternary structure of
trimeric Env was achieved by crystallographic and cryo-electron
microscopy (cryo-EM) studies of soluble, cleaved forms of the
Env trimer (Bartesaghi et al., 2013; Julien et al., 2013a; Lyumkis
et al., 2013). The gp120-gp41 protein for two of these studies
was produced using a stabilized form of the HIV-1 strain
BG505 trimer that had antigenic properties corresponding to
native Env (Sanders et al., 2013). The 4.7 A˚ crystal structure (in
complex with a V3 stem-specific bNAb PGT122) and the 5.8 A˚
cryo-EM reconstruction (fully glycosylated trimer in complex
with theCD4-binding site antibody VRC-PG04) revealed the intri-
cate arrangement of the V1/V2 and V3 loops at the apex of the
trimer as well as the locations of gp41 helices HR1 (forming a
three-helix bundle along the trimer axis) and HR2 (at the outer
edge of the trimer base). These structureswill be useful for immu-634 Cell 156, February 13, 2014 ª2014 Elsevier Inc.nogen design by revealing the full extent
and context of the antibody targets.
bNAbs against HIV-1
Despite the ability of HIV-1 to evade the
antibody response, a small fraction ofinfected individuals eventually develop high titers of broadly
neutralizing serologic activity (Doria-Rose et al., 2009; Gray
et al., 2011; Mikell et al., 2011; Sather et al., 2009). Initial
attempts to characterize and map these responses were mostly
limited to serum adsorption studies on a polyclonal level (Binley
et al., 2008; Li et al., 2007), and only a few potent and broadly
neutralizing monoclonal antibodies were described until 2009.
These antibodies targeted the CD4-binding site, the MPER, a
cluster of high mannose glycans, and the variable loops, and,
although not very potent, the antibodies neutralized multiple
lab-adapted and/or primary isolates from several HIV-1 sub-
types establishing the principle that antibodies to HIV-1 can
have neutralizing breadth (Burton et al., 1994; Gorny et al.,
1992; Muster et al., 1993; Scott et al., 1990; Tilley et al., 1991;
Trkola et al., 1996; Zwick et al., 2001).
Beginning in 2009, with the introduction of single-cell antibody
cloning techniques to characterize the anti-HIV antibody
response (Scheid et al., 2009), dozens of broad and potent
monoclonal antibodies have been cloned from infected individ-
uals. The best of these are two to three orders of magnitude
more potent than the previously characterized antibodies and
can neutralize up to 90% of the HIV-1 isolates tested. Occa-
sionally, individual monoclonal antibodies can account for the
activity in serum (Walker et al., 2011a; Wu et al., 2010), but
breadth and potency are most frequently attributed to a com-
bination of unrelated antibodies that target different sites of
vulnerability on the Env spike (Georgiev et al., 2013; Klein
et al., 2012a; Moore et al., 2012; Sather et al., 2012; Scheid
et al., 2009; Scheid et al., 2011; Wibmer et al., 2013). The targets
of the new antibodies can be divided into the following major
groups: (1) CD4-binding site, (2) N-linked glycan-containing
epitopes, and (3) the membrane proximal external region
(MPER). In addition, there are yet to be defined conformational
epitopes, e.g., antibody 3BC176 (Klein et al., 2012a) (Figure 1).
CD4-Binding Site Antibodies
Since the CD4-binding site on gp120 is the site of initial host
receptor interaction it cannot be completely masked by
Figure 2. bNAb Recognition Modes for the
CD4-Binding Site
(A) CD4-mimetic: NIH45-46 (magenta) (Diskin
et al., 2011) versus CD4 (yellow).
(B) CDR H3 loop-based: CH103 (purple) (Liao
et al., 2013) versus CD4 (yellow). Structures of the
complexes are shown as Ca traces aligned on
gp120. The top views display gp120 in a surface
representation with the CD4 binding-loop high-
lighted (salmon). The bottom views display close-
up views showing the Ca trace of gp120 (green).conformational changes or the glycan shield, and therefore it is
potentially vulnerable. Moreover, it must be conserved between
strains to maintain its function. It is not an easy target, however,
because the site is a recessed pocket that accepts the terminal
immunoglobulin-like domain of CD4 (Kwong et al., 1998). Fitting
into the CD4-binding pocket is a challenge for the larger antigen-
binding unit of an antibody, which is composed of paired immu-
noglobulin domains (variable heavy and variable light, VH and VL).
Nevertheless, the human immune system has found at least two
distinct ways to produce antibodies that can access this site.
One way mimics CD4 itself, by positioning the antibody VH
domain to bind gp120 using primarily the complementarity
determining region (CDR) H2 loop and framework residues
(Zhou et al., 2010) and engaging the CD4-binding loop on
gp120 with backbone atoms in the C00 strand of VH (Diskin
et al., 2011; Wu et al., 2011; Zhou et al., 2010) (Figure 2A). The
antibodies in this class are CD4 mimetics because the VH
domain occupies the same position as the terminal immuno-
globulin-like domain of CD4 and both use the C00 strand to
interact with the CD4-binding loop of gp120 (Zhou et al., 2010).
The other mode of CD4-binding site recognition is exemplified
by antibody CH103 (Liao et al., 2013). This mode of recognition
does not mimic CD4 but uses the antibody’s CDR H3 loop to
reach the CD4-binding loop (Figure 2B).
There are two groups of CD4-mimetic bNAbs; those that
derive from the IgH VH1-2 germline gene segment (typified by
VRC01 (Wu et al., 2010)), and those that derive from the
VH1-46 gene segment (Scheid et al., 2011). The number
of independently developed antibodies in the VH1-2 group is
remarkable—antibodies binding gp120 in essentially the sameCell 156,manner have been isolated from seven
different infected individuals (Georgiev
et al., 2013; Scheid et al., 2011; Wu
et al., 2010; Wu et al., 2011; Zhou et al.,
2013). Antibodies belonging to this group
share heavy chain signature residues
including Trp50, Asn58, Arg71, and
Trp100B (West et al., 2012). Inspection
of human VH gene sequences and usage
frequencies reveals that VH1-2 is by
far the most common germline gene
segment that encodes Trp50, Asn58,
and Arg71 (Trp 100B is in CDR H3 and
not derived from the VH gene segment).
The dependence on antibody structural
regions that are less likely to be shapedby recombination and somatic hypermutation may help to
explain the restricted usage of VH genes observed for this class
(Diskin et al., 2011; Scheid et al., 2011; Zhou et al., 2013). A
number of different kappa and lambda light chain gene seg-
ments can be paired with VH1-2 to produce CD4-mimetic
antibodies, but some commonalities of the light chains are
notable. These are due in part to the requirement for the light
chain to avoid steric clashes with gp120. First, the length of
CDR L3 is restricted to five amino acids (which occurs in only
about 1% of human light chains) (West et al., 2012). Second,
the CDR L1 loop appears to require either a relatively short
loop or the presence of glycine residues to confer sufficient
flexibility to avoid unfavorable interaction with gp120 (Diskin
et al., 2011; Zhou et al., 2013) (Figure 2A).
Unlike the VH1-2 group of CD4-mimetic antibodies, the VH1-
46 antibodies do not have short CDR L3 loops and lack Trp50,
Asn58, and Trp100B (Scheid et al., 2011). The known represen-
tatives of the VH1-46 class (isolated from two individuals) are not
as potent as the VH1-2 class (Chuang et al., 2013; Scheid et al.,
2011). The VH1-2 and VH1-46 gene segments are closely
related, suggesting that common features of these germline
genes are particularly compatible with the CD4-mimetic binding
mode (Kwong et al., 2013).
While the VH1-2 and VH1-46 classes of CD4-binding site
antibodies mimic CD4 by using framework residues and CDR
H2, another group of CD4-binding site antibodies uses long
CDRs to reach into the recessed CD4-binding site. For this
group, the main interface with gp120 is formed by the CDR H3
loop (Figure 2B). The first of these antibodies to be characterized
was b12, which is a phage display-derived antibody in which theFebruary 13, 2014 ª2014 Elsevier Inc. 635
Figure 3. Multiple Approach Angles for Antibodies Targeting the
N-Linked Glycan Attached to Asn332
Surface overlay of aligned complexes. Structures shown: gp140, gray (Liu
et al., 2008); Asn332 glycan, yellow; PGT128, green (Pejchal et al., 2011);
2G12, magenta (Calarese et al., 2003); and PGT135, blue (Kong et al., 2013).heavy chain was paired with a noncognate light chain (Burton
et al., 1994). Antibody CH103, which was cloned by single-cell
methods from an infected individual (Liao et al., 2013), also rec-
ognizes the CD4-binding site loop using CDR H3. This antibody
is considerably broader and more potent than b12; it recognizes
a surface that overlaps well with the site of CD4 contact. Less is
known about other naturally arising non-CD4-mimetic bNAbs
including HJ16 (Corti et al., 2010; Pietzsch et al., 2010). To
date, the antibodies targeting the CD4-binding site by non-
CD4-mimetic mechanisms are less broad and potent than the
CD4 mimetic antibodies, but fewer of this class of antibodies
have been cloned. The non-CD4-mimetic Abs do not seem to
have a strong preferential germline V gene usage, consistent
with binding primarily dependent on their CDR H3 sequence.
N-Linked Glycan-Containing Epitopes
Although the glycan shield of the HIV-1 Env is generally effective
in blocking antibody access to potential protein epitopes, bNAbs
can avert this mode of escape by including the glycans them-
selves as part of their target (McLellan et al., 2011; Mouquet
et al., 2012a; Pancera et al., 2013a; Walker et al., 2011a; Walker
et al., 2009). Bacterial pathogen-specific anti-carbohydrate anti-
bodies commonly recognize pathogen-derived glycans that are
distinct from host carbohydrates. In contrast, the specific recog-
nition of host-derived glycans on the HIV-1 spike is a more chal-
lenging task because potentially harmful anti-self antibodies are
generally removed from the repertoire during B cell development
(Wardemann et al., 2003). HIV-1 antibodies whose epitopes
include N-glycans solve this problem because they do not
recognize isolated self-glycans. Instead they recognize combi-
nations of glycans and nearby protein features (V1/V2- and V3-
glycan-dependent antibodies), and/or they bind to two or more
glycans with a precise geometrical relationship that does not
normally exist on host glycoproteins (2G12). In contrast to the636 Cell 156, February 13, 2014 ª2014 Elsevier Inc.common recognition mode of the VH1-2 class of CD4-binding
site antibodies, each of the recently isolated bNAbs recognizing
N-linked glycan-containing epitopes have solved this recogni-
tion puzzle in a distinct way.
Asn332 Glycan-V3
The largest and most diverse group of bNAbs recognizing
N-linked glycan-containing epitopes targets a region adjacent
to the highly conserved PNGS at Asn332, which includes the
base of the gp120 V3 loop and several nearby glycans. Whereas
antibodies to the CD4-binding sitemust approach by a restricted
angle, bNAbs targeting the region centered on Asn332 approach
the site from several different angles (Kong et al., 2013; Pancera
et al., 2013b) (Julien et al., 2013a; Lyumkis et al., 2013) (Figure 3).
The bNAbs that recognize this region include 2G12 (Scanlan
et al., 2002; Trkola et al., 1996), PGT128 (Pejchal et al., 2011;
Walker et al., 2011a), PGT121/10-1074 (Mouquet et al., 2012a;
Walker et al., 2011a), and PGT135 (Kong et al., 2013; Walker
et al., 2011a).
2G12 recognizes a cluster of high-mannose glycans attached
to Asn332, Asn295, and Asn339 using a unique domain-
swapped architecture that combines both Fab arms into a single,
large antigen-binding (Fab)2 unit (Calarese et al., 2003). Domain-
swapped dimers of 2G12 show higher neutralization potency
and breadth (West et al., 2009) through binding of two (Fab)2
units that are flexibly linked to two Fc regions in the 2G12 dimer
(Wu et al., 2013). PGT128 recognizes an epitope that includes
N-glycans attached to Asn332 and Asn301 in combination with
amino acid residues near the C-terminal end of the V3 loop
(Pejchal et al., 2011). PGT128 recognizes and penetrates the
glycan shield using a long CDR H3 loop and a CDR H2 loop
with a six amino acid insertion. PGT121, PGT122, and 10-1074
are clonal relatives that represent a separate group of bNAbs
recognizing the glycan attached to Asn332 in combination with
amino acid residues at the base of the V3 loop and a glycan
attached to V1/V2 (Mouquet et al., 2012a) (Julien et al., 2013a;
Julien et al., 2013c; Lyumkis et al., 2013). These antibodies are
the most potent among the Asn332-dependent antibodies, but
they are not as broad as the anti-CD4-binding site antibodies
because they lack activity against many clade A and C strains
(Mouquet et al., 2012a; Walker et al., 2011a).
Structural and biochemical studies of 10-1074 and PGT121
provided the first characterization of HIV-1 epitopes involving
complex-type N-glycans and suggested that some glycan-
specific HIV-1 antibodies can exhibit promiscuous recognition
of N-glycans through binding to the pentasaccharide core
common to both high-mannose and complex-type N-glycans
(Mouquet et al., 2012a). This type of glycan recognition may be
an adaptation to the varying proportions of high-mannose- and
complex-type N-glycans found on HIV-1 Env within a single
strain of virus at any particular PNGS. Further definition of the
epitope of the PGT121/10-1074 clonal family has been provided
by the crystal structure of the Env trimer bound to the PGT121/
10-1074 clonal relative PGT122 (Julien et al., 2013a). As ex-
pected, the glycan attached to Asn332 is the central feature of
the epitope, contacted by the long CDR H3 loop and by CDR
L2. The glycan attached to Asn137 in the V1 loop of BG505
gp120 occupies the groove previously observed to bind complex
glycans (Julien et al., 2013c; Mouquet et al., 2012a). The glycan
attached to Asn301, which has a significant effect on PGT122
neutralization, is contacted by the light chain framework region
3 (Julien et al., 2013a). Precisely how this group of antibodies
neutralizes HIV-1 is not known, but it has been proposed that
they allosterically prevent CD4 binding (Julien et al., 2013c).
Another antibody that depends on Asn332-linked carbohydrate,
PGT135, recognizes glycans attached to Asn332, Asn392, and
Asn386 using long CDR H1 and H3 loops to reach through the
glycan shield, contacting glycans and peptide residues
belonging to two adjacent b strands connected to the V3 and
V4 loops (Kong et al., 2013).
Asn160 Glycan-V1/V2
A second group of glycan-binding bNAbs recognizes the glycan
attached to Asn160 in conjunction with nearby peptide residues.
This epitope is conformation-dependent, and it is recognized by
antibodies PG9 and PG16 (Walker et al., 2009), CH01-CH04
(Bonsignori et al., 2011), and PGT141-PGT145 (Walker et al.,
2011a). PG9 has a hammerhead-like 28-residue CDR H3 loop
that binds to glycans attached to Asn160 and Asn156 and one
b strand of the V2 domain (McLellan et al., 2011). PG9 appears
to contact two gp120 monomers at the apex of the HIV-1 trimer
(Julien et al., 2013b). Onemight speculate that the binding of this
class of antibodies to the Env trimer interferes with its orderly
disassembly during the fusion process. Another possibility that
is supported by binding studies using Env trimers expressed
on virus-like particles is that a single PG9- or PG16-binding event
induces a coordinated change to a trimer state incapable of CD4
binding (Lo¨ving et al., 2013). PG16 fails to completely neutralize
some sensitive viral isolates even at very high antibody concen-
trations (Walker et al., 2009) probably because it has an absolute
requirement for high-mannose N-glycans and therefore cannot
neutralize virions bearing heterogeneous glycans at position
Asn160.
Asn234 and Asn276 Glycans
The third and smallest class of glycan-dependent anti-HIV-1
antibodies is represented by 8ANC195, which is one of only
two clonal relatives belonging to this class of antibodies to
date (Scheid et al., 2011). Neutralization by this antibody
depends on glycans attached to positions Asn234 and Asn276
(Chuang et al., 2013; West et al., 2013) in a region adjacent to
the CD4-binding site. Binding and neutralization experiments
indicate that 8ANC195 recognizes either high-mannose
N-glycans or the core pentasaccharide common to both
complex-type and high-mannose N-glycans. Although the
8ANC195 epitope appears to be different from previously-
characterized epitopes (Chuang et al., 2013; West et al., 2013),
the structure of liganded 8ANC195 has not yet been reported,
and therefore its precise mode of binding, its protein contact
residues if any, and its mode of interference with viral entry are
not known.
MPER Epitopes
The bNAbs 4E10, 2F5, Z13, 10E8, and m66.6 recognize linear
epitopes in the MPER of gp41 (Huang et al., 2012; Nelson
et al., 2007; Zhu et al., 2011; Zwick et al., 2005). The MPER con-
tains conserved residues that presumably play a critical role in
the fusion process. The transient exposure of this region (Alam
et al., 2009; Frey et al., 2008; Sattentau et al., 1995), steric factors
(Klein et al., 2009), hydrophobicity (Haynes et al., 2005), and hostmimicry (Finton et al., 2013; Haynes et al., 2005; Yang et al.,
2013) appear to limit the frequency with which bNAbs to this
region are elicited. Moreover, the partially buriedMPER epitopes
tend to elicit hydrophobic and polyreactive antibody paratopes
(Haynes et al., 2005; Sun et al., 2008), which are usually selected
against during B cell development (Chen et al., 2013; Doyle-
Cooper et al., 2013; Mouquet and Nussenzweig, 2012; Verkoczy
et al., 2010; Wardemann et al., 2003). Finally, antibodies against
linear MPER epitopes appear to be selected against because of
potential autoreactivity against MPER sequences that are also
found in human proteins; human kynureninase contains the
2F5 epitope (ELDKWA), and the 4E10 recognizes a motif in
splicing factor 3b subunit 3 (SF3B3) (Yang et al., 2013) and an
inositol triphosphate receptor (Finton et al., 2013). Not all B cells
expressing such antibodies are deleted, however, as demon-
strated by the ability of MPER peptide liposomes to trigger
expansion and activation of residual anergic B cells in a mouse
model (Verkoczy et al., 2013).
A Distinct Conformational Epitope
The clonal bNAb variants 3BC176 and 3BC315 appear to recog-
nize a distinct conformational epitope on the spike trimer, but the
location of their binding site on the HIV-1 Env remains to be
determined (Klein et al., 2012a).
Unusual Features of Anti-HIV-1 bNAbs
HIV-1 infection in humanized mice and SHIV infection in
macaques can be prevented by passive transfer of bNAbs (Klein
et al., 2013b; Kramer et al., 2007; Mascola and Montefiori, 2010;
Watkins et al., 2011). Although it is therefore widely believed that
a vaccine that elicits such antibodies would be effective in pro-
tecting against HIV-1 infection, extensive experimentation in
animal models and clinical trials in humans have not elicited
these antibodies by vaccination (McCoy and Weiss, 2013).
One key question in this area of biology is why not?
Molecular characterization of the newly available bNAbs and
their interactions with antigen has provided some clues to under-
standing why these antibodies are difficult to elicit. Antibody
variable domains can be divided into structurally diverse CDRs
that usually contact the antigen and relatively invariant frame-
work regions (FWRs) (Figure 4). The heavy chain CDR H3 is
usually the most important of the six CDRs. It is highly variable
because it is assembled by random and imprecise joining of
the variable (V), diversity (D), and joining (J) region gene seg-
ments of the antibody gene during V(D)J recombination.
CDR Loops
Many bNAbs have unusually long or short CDR loops. The length
of CDR3 regions of the heavy and light chain variable domains is
normally determined by N and P nucleotide addition and by
resection of DNA ends during V(D)J recombination (Fugmann
et al., 2000; Jung et al., 2006). Antibodies with very long CDR
H3 loops are frequently deleted at the first tolerance checkpoint
(Meffre et al., 2001). In humans the average CDR H3 is 16 resi-
dues (Tiller et al., 2007), but in PGT145 the CDRH3 is 33 residues
(CDR lengths based on the IMGT definition)(Lefranc, 2011;
Walker et al., 2011a). Other HIV-1 bNAbswith longCDRH3 loops
include PG9/PG16 (30); CH01-CH04, PGT121, 10-1074 (26); 2F5
(24); 10E8, 8ANC195 (22); PGT127, PGT128, HJ16 (21); 4E10,
b12, and PGT135 (20). In some cases such as PG9/PG16, theCell 156, February 13, 2014 ª2014 Elsevier Inc. 637
Figure 4. Antibody Structure Showing FWR
and CDR Regions
(A) Side + top view of ribbon diagram with color-
coded FWR and CDR regions.
(B) Side + top view of surface diagram with color-
coded FWR and CDR regions. HC, dark blue, LC,
light blue; CDRHs, magenta; CDRLs, teal.
(C) Map of the FWR and CDR regions of the heavy
and light variable domains.long CDR H3 loops permit penetration of the glycan shield,
whereas in others such as the anti-MPER antibody 2F5, the
CDR H3 binds its linear epitope and extends a hydrophobic
patch into the viral membrane (Ofek et al., 2010). Long CDR3s
are not obligate features of bNAbs against HIV-1, however. For
example, the group of CD4-mimetic bNAbs derived from VH1-
2, which include some of the broadest and most potent bNAbs,
have unusually short CDR L3 loops of only five amino acids (West
et al., 2012).
Somatic Mutation
The one feature shared by all anti-HIV-1 bNAbs characterized to
date irrespective of their target site on the HIV-1 spike is a high
degree of somatic hypermutation. Most affinity-matured human
VH domains carry 15–20 somatic mutations at the nucleotide
level (Tiller et al., 2007), while anti-HIV-1 antibodies are generally
more extensively mutated (Scheid et al., 2009), and members of
the bNAb subset of anti-HIV-1 antibodies carry 40–100 VH gene
mutations (Klein et al., 2013a; Mouquet et al., 2012a; Scheid
et al., 2011; Walker et al., 2011a; Walker et al., 2009; Wu et al.,
2010; Wu et al., 2011; Xiao et al., 2009). These mutations are
essential for the binding and neutralizing activity of the bNAbs
since reverting the antibodies to their germline coding sequence
results in complete loss of neutralizing activity (Hoot et al., 2013;
Klein et al., 2013a; Liao et al., 2013; Scheid et al., 2011; Zhou
et al., 2010).
Somatic mutations are introduced into antibody genes by the
enzyme activation-induced cytidine deaminase (AID), which is
expressed in B cells undergoing clonal expansion in the germinal
center (Victora and Nussenzweig, 2012). The same enzyme also
produces insertions and deletions, which are rare in most anti-
bodies but common among bNAbs (Klein et al., 2013a; Victora638 Cell 156, February 13, 2014 ª2014 Elsevier Inc.and Nussenzweig, 2012). Since muta-
tion is random, it can lead to autore-
activity, decreased affinity, or have no
effect. AID is preferentially targeted to
the CDRs and not to the FWRs because
the latter have fewer sequences that
serve as AID hotspots. In addition, the
nucleotide code in the framework regions
has evolved to be maximally tolerant
of mutational base changes without
affecting the amino acid sequence (Rey-
naud et al., 1995; Wagner et al., 1995).
This is an essential protective feature of
the mutational mechanism because
mutations that alter the FWRs can
destroy the antibody fold, whereas muta-
tions in the CDRs are more easily toler-ated since they are in loops that do not affect the structural
underpinnings of the antibody domain (Figure 4). Thus, while
FWR mutations occur in mature antibodies, these nucleotide
alterations generally do not alter antigen binding (Jones et al.,
1986). For example, the neutralizing activity of broadly neutral-
izing anti-influenza antibody FI6 was not affected by reverting
framework mutations (Corti et al., 2011). Indeed the relatively
constant nature of the FWR explains why mouse monoclonal
antibodies can be humanized for use as therapeutics in humans
by creating chimericmolecules bearingmouseCDRs and human
FWRs (Jones et al., 1986).
Consistent with these observations, reverting the FWRs to
germline in anti-HIV-1 antibodies with limited breadth and
potency had little effect on their activity (Klein et al., 2013a). In
contrast, FWR mutations were critical for anti-HIV-1 bNAb
neutralization and binding. Reversion of the FWR to germline
eliminated binding and neutralizing activity for nearly all of the
bNAbs tested even when FWR contact residues were spared
and only noncontact residues were reverted (Klein et al., 2013a).
Why are FWRmutations essential for HIV-1 bNAb breadth and
potency? In some cases, FWR residues contribute to bNAb
binding directly by contacting the antigen. For example in the
CD4-binding site antibodies VRC01, NIH45-46, 12A12, and
12A21, FWR residue 74 is mutated from Ser to Tyr, and the larger
aromatic residue forms hydrogen bonds with main chain atoms
of the gp120 bridging sheet. In another CD4-binding site
antibody, 3BNC117, somatic hypermutation introduced a four
amino acid insertion in the FWR3 that is essential for neutraliza-
tion of certain viral strains and might bridge the CD4-binding site
epitope with V1/V2 residues (Klein et al., 2013a; Scheid et al.,
2011; Zhou et al., 2013).
In bNAbs recognizing N-linked glycan-containing epitopes,
FWR mutations can play at least two roles; in 2G12 they
contribute to the assembly of the contact surface between the
domain-swapped VH domains that form its unusual tripartite
antigen-binding site (Calarese et al., 2003). In PGT135, as in
CD4-mimetic antibodies, FWR mutations also contribute the
direct contacts between antigen and antibody; for example, light
chain FWR residue 63 is mutated from Ser to Val, which allows
van der Waals contacts with mannose residues on the glycan
attached to gp120 residue Asn392 (Kong et al., 2013). Finally,
FWR mutations can also contribute to breadth and potency by
increasing the overall flexibility of the antibody. For example, a
FWR mutation in 3BNC60 introduces a Pro that disrupts the
main chain hydrogen bonding between VH domain strands C
0
and C00 (Klein et al., 2013a). Reversion of this mutation greatly
reduced the neutralization potency of 3BNC60 against more
than a third of strains tested, indicating that the conformational
flexibility provided by this FWR mutation was often critical. In
conclusion, FWR mutations contribute to the activity of bNAbs
in a number of different ways, and they are a consistent feature
of the most broad and potent anti-HIV-1 antibodies irrespective
of their Env target sites.
Polyreactivity
HIV-1 antibodies are frequently polyreactive, which means that
they bind to numerous non-HIV-1 antigens, although with rela-
tively low affinities. Highly polyreactive antibodies are removed
from the B cell repertoire during development (Wardemann
et al., 2003), but anti-HIV-1 antibodies appear to be an exception
to this rule (Haynes et al., 2005; Mouquet and Nussenzweig,
2012). One potential explanation for this unexpected finding is
that the low density of Env spikes and Env trimer geometry
generally prevent bivalent binding (Klein and Bjorkman, 2010),
and polyreactivity is selected as a means of providing a second
binding interaction for anti-HIV antibodies (Mouquet et al., 2010).
For example, lipid binding by bNAbs 2F5 and 4E10 has been
proposed to increase the local concentration of these anti-
MPER antibodies in the vicinity of their gp41 epitopes (Alam
et al., 2009). In a proof-of-concept experiment that supports
this idea, bivalent anti-HIV reagents with one Fab unit targeting
gp120 neutralizing epitopes and the other targeting a non-
neutralizing gp41 epitope showed enhanced anti-HIV potency
(Mouquet et al., 2012b).
Vaccination to Produce Anti-HIV-1 Neutralizing
Antibodies
An important unresolved issue is why only certain infected indi-
viduals produce these bNAb responses to HIV-1. It is possible
that the ability to produce bNAbs is determined by host genetic
factors, but there are as yet no studies that support this hypoth-
esis (Euler et al., 2013). An alternative possibility, first suggested
by studies inmacaques, is that the initial envelope sequence that
the immune system encounters is an important determinant of
whether or not neutralization breadth develops (Shingai et al.,
2012; Walker et al., 2011b). Two SHIVs that differ only in their
Env sequences elicit distinct neutralizing antibody responses in
infected macaques. SHIVAD8 elicited neutralizing breadth in
most infected animals, while only 1 out of 36 macaques infected
with SHIVDH12 developed breadth (Shingai et al., 2012).The idea that the Env sequence, or the antigen, is one of the
factors that favors development of bNAbs is also supported by
recent longitudinal observations on a superinfected patient
who developed neutralizing breadth (Doria-Rose et al., 2014).
Although two viruses were present in that individual, bNAbs
developed in response to only one of the two viruses, and there-
fore one virus was better than the other in eliciting the response
in this individual. Moreover, it appears that patients that are
superinfected have a higher probability of developing neutral-
izing breadth (Cortez et al., 2012; Powell et al., 2010) possibly
because their immune systems are exposed to a larger number
of envelope sequences and therefore have a higher likelihood of
encountering one that can initiate and then shepherd the
appropriate response.
Given the remaining uncertainties about how bNAbs develop
in infected individuals, two approaches to vaccination have
been proposed: (1) rational immunogen design based on
the structure of bNAbs and their ligands (Burton et al.,
2012; Sattentau and McMichael, 2010; Zolla-Pazner, 2004);
(2) reproduction of the naturally-occurring pathway to bNAb
development by replicating what happens in individuals who
exhibit serologic breadth and potency (Haynes et al., 2012;
Liao et al., 2013; Scheid et al., 2009; Wibmer et al., 2013).
As reviewed above, many of the important molecular details of
the interactions between bNAbs and Env have been described.
However, the first group of HIV-1 immunogens designed based
on these interactions failed to elicit bNAbs in experimental
animals (Burton et al., 2012; Kwong and Mascola, 2012). An
unappreciated problem at the time of their design was that
most of the unmutated germline precursors of the bNAbs do
not bind to HIV-1 spike proteins from most viral isolates (Hoot
et al., 2013; Klein et al., 2013a; Scheid et al., 2011; Zhou et al.,
2010). Therefore, B cells producing bNAb precursors could not
be recruited into immune responses by these immunogens.
Although MPER peptides and a gp41 fusion intermediate
peptide mimic bind to the germline precursor of 2F5 with
modest affinity (Alam et al., 2011), the B cells expressing these
antibodies are cross-reactive with autologous antigens and likely
deleted during development (Finton et al., 2013; Haynes et al.,
2005; Wardemann et al., 2003; Yang et al., 2013).
New approaches to structure-based design have succeeded
in engineering immunogens that bind to the unmutated VRC01
class precursors (Jardine et al., 2013; McGuire et al., 2013). In
addition, chemically synthesized oligomannose V1/V2 glyco-
peptides have been developed that bind to the germline precur-
sors of PG9 andCH01 (Alam et al., 2013). In theory, immunization
with members of this new generation of antigens should expand
the pool of B cells that carry the bNAb precursors. However,
recruiting these B cells into the immune response may not to
be sufficient to produce breadth or potency, which only appear
to develop with extensive somatic mutation and selection in
the germinal center (Victora and Nussenzweig, 2012).
Typical high-affinity human antibodies that develop in
response to pathogens carry only 10–15 somatic mutations
(Tiller et al., 2007). By first principles, immunization with an
HIV-1 protein, including a rationally-designed immunogen,
should also produce high-affinity antibodies. But repeated
boosting with the immunogen will not significantly alter affinityCell 156, February 13, 2014 ª2014 Elsevier Inc. 639
Figure 5. Arms Race between Antibodies
and HIV
(A) Interplay between evolving antibody response
and Env trimer. Antibodies acquire a growing
number of somatic mutations, shown as colored
bars in the antigen binding region of the antibody.
The mutations arise in germinal centers and are
responsible for increasing breadth and potency.
Rapid escape by mutation in Env is shown as a
color change in the trimer.
(B) Successive emergence of broadly neutralizing
antibodies (Wibmer et al., 2013). Following an
initial strain-specific antibody response, a V2-
specific bNAb emerges (red wave). Escape from
the initial bNAb produces amutant virus that elicits
a CD4-binding site bNAb (blue wave). This
response is followed by a third wave against an
unknown epitope, shown as a green wave.or result in additional accumulation of somatic mutations
because affinity-based selection in the germinal center selection
is physically limited by two invariant parameters: diffusion and
the rate of antigen internalization (Batista and Neuberger,
1998; Foote and Milstein, 1991). Affinity is a ratio of the on-
and off-rates of the antigen-antibody complex. The on-rate is
diffusion limited. The off-rate is limited by the rate of antibody
internalization by the B cell because once the antigen is inside
the cell it will be degraded irrespective of affinity for the mem-
brane-bound antibody on the cell surface. Moreover, memory
B cells with high-affinity antigen receptors are typically shunted
away from the germinal center fate to become antibody-
producing plasma cells (Victora and Nussenzweig, 2012).
So how do anti-HIV-1 bNAbs accumulate 40–100 mutations in
their heavy chain variable genes?Onepossibility is that high rates
of mutation reflect the ongoing arms race between the virus and
the antibody system that involves repetitive cycles of germinal
center maturation (Klein et al., 2013b; Liao et al., 2013; Scheid
et al., 2009; Scheid et al., 2011; Wibmer et al., 2013)
(Figure 5A). According to this model, the initial production of a
strain-specific neutralizing antibody results in selection for anti-
body-resistant viral variants that are no longer efficiently neutral-
ized and are only recognized by the antibodywith lowaffinity. The
low-affinity interactions between the strain-specific antibody and
the newly resistant viral variant would allow B cell recruitment to
an additional round of affinity maturation and mutation in the
germinal center leading to the development of an antibody that
neutralizes the initial escape variant and selects for a second
generation of antibody-resistant variants (Klein et al., 2013a;640 Cell 156, February 13, 2014 ª2014 Elsevier Inc.Klein et al., 2013b). Iterative cycles of viral
escape and antibody maturation would
eventually produce highly mutated anti-
bodies that recognize a broad spectrum
of HIV-1 viruses. An additional possibility
is that escape mutations in Env render
previously shielded sites open to anti-
body recognition and the recruitment of
newantibodies into the anti-HIV response
(Wibmer et al., 2013).
Both the germinal center recycling and
the epitope exposure due to escapemodels are supported by recent retrospective studies that
traced the parallel evolution of HIV-1 antibody responses (Liao
et al., 2013; Moore et al., 2012; Wibmer et al., 2013). Liao and
colleagues traced the development of an anti-CD4-binding site
antibody in a single individual (Liao et al., 2013). As might be pre-
dicted, the B cell clone that was initially expanded in response to
infection produced an antibody that bound to and neutralized the
transmitted founder virus but failed to neutralize rapidly
emerging variants. However, ongoing somatic hypermutation
of the original B cell clone produced bNAbs that neutralized
the emerging HIV-1 variants and gained breadth as a result.
Similar results have been reported for the development of a
bNAb targeting the V1/V2 region (Doria-Rose et al., 2014).
Reproducing the development of such antibodies might require
a new type of vaccination scheme involving the use of specific
Env proteins to recruit B cells expressing the germline antibody
precursor and subsequent immunizations with antigens repre-
senting antibody escape variants.
Further insights into the development of bNAbs have been
provided by studies by Moore and colleagues (Moore et al.,
2012; Wibmer et al., 2013) (Figure 5B). These studies reveal
how viral escape from early strain-specific neutralizing anti-
bodies may drive the development of bNAbs through sequential
recognition of multiple epitopes. In the first study, viral escape
from a strain-specific antibody induces the appearance of a
new epitope (containing an N-linked glycan attached to
Asn332) that is subsequently recognized by a bNAb (Moore
et al., 2012). A fuller picture of the interplay of antibody develop-
ment and viral escape was revealed by characterizing the
sequential and transient appearance in one individual of three
distinct bNAb specificities over the first 4.5 years of infection
(Wibmer et al., 2013). After escape from a strain-specific anti-
body targeting an unusual V2 epitope, a series of bNAbs devel-
oped targeting V2, the CD4-binding site, and an uncharacterized
quaternary epitope. A common feature of these events was that
escape from one antibody specificity exposed new targets for
recognition (Figure 5B).
Speculative General Scenario for the Development of
bNAbs and Vaccination
HIV-1 Env has evolved such that potent bNAbs are rarely, if ever,
generated from the human antibody repertoire by the initial
exposure to the transmitted viral strain. Many strain-specific
antibodies develop that the virus readily escapes. However,
the presence of these strain-specific antibodies in serum has
the effect of reducing the Env sequence space available for
escape from new antibodies. Perhaps a year, or in some cases
more time, is required before this effect becomes significant.
Then, when a new antibody develops for which the virus has
more limited avenues for escape, an incipient bNAb is able to
‘‘chase’’ the mutating virus, undergoing germinal center matura-
tion and developing breadth. This process contrasts with the
early strain-specific antibodies that are not able to overcome
escape mutations. Ultimately, in the face of a potent bNAb, the
virus must completely escape the bNAb’s chase by mutating
to a less-fit form that may subsequently restore its fitness by
secondary mutations.
An HIV-1 vaccine may have to mimic this sequential approach
starting with immunogens designed to engage the appropriate B
cell precursors followed by iterative boosts with naturally occur-
ring Envs associated with the development of bNAbs. Given the
nature of the physiologic process that leads to production of
bNAbs, it is highly unlikely that repeated vaccination with a single
monomorphic antigen could elicit a broadly active vaccine.
Immunotherapy with Anti-HIV-1 Antibodies
The idea that antibodies could be used to treat infectious
diseases was first proposed by Kitasato Shibasaburo and Emil
von Behring over 100 years ago. In the 20th century antibiotics
rapidly replaced serum therapy for infectious diseases, and
today antibodies are in clinical use primarily for inflammatory
diseases and cancer.
Like many other infections, HIV-1 can be treated with conven-
tional small-molecule drugs. Combinations of antiretroviral
drugs that target different aspects of the viral life cycle are partic-
ularly effective in controlling viremia (Grant and Zolopa, 2010;
Olender et al., 2012; Simon et al., 2006; Vergidis et al., 2009).
Therapy must be continued indefinitely, however, because
antiretroviral therapy (ART) fails to eliminate latent viral reservoirs
and viremia rebounds as soon as the drugs are discontinued
(Hamlyn et al., 2012).
Antibodies differ from ART in a number of important ways that
might be useful in therapeutic approaches to HIV-1 and
may complement small-molecule-based approaches to HIV-1
treatment. For example, antibodies usually have a half-life of
14–21 days in humans, which means that they may only have
to be administered once every 2–4 months. In addition to their
direct neutralizing effects, antibody effector functions mediatedthrough the Fc region expedite viral clearance from circulation
(Igarashi et al., 1999; Nimmerjahn and Ravetch, 2008). Through
antibody-dependent cellular cytotoxicity (ADCC), antibodies
can engage diverse effector cells such as NK cells, monocytes,
and activated macrophages to kill HIV-1-infected target cells.
Finally, some broadly neutralizing antibodies can interfere with
cell-to-cell spread of HIV-1 (Malbec et al., 2013).
The idea that antibodies might be useful adjuncts to standard
HIV-1 therapy was initially tested over a decade ago in human-
ized mice and later in clinical trials in infected individuals using
combinations of first generation bNAbs (Mehandru et al., 2007;
Poignard et al., 1999; Trkola et al., 2005). Humanized mice
were infected with HIV-1JR-CSF or HIV-1SF162 and treated with
high concentrations of a mixture of b12 (a CD4-binding site
antibody), 2G12 (a glycan-specific antibody) and 2F5 (an
anti-MPER antibody). This mixture failed to control viremia.
Indeed, triply resistant viral variants were reported to emerge
within one week of initiation of therapy, and it was concluded
that antibodies would be unable to control viremia due to rapid
escape (Poignard et al., 1999).
Human trials re-enforced the conclusions of the mouse
studies (Mehandru et al., 2007; Trkola et al., 2005). Two indepen-
dent groups of investigators treated individuals infected with
antibody-sensitive HIV-1 strains using a combination of the
anti-glycan bNAb 2G12 and anti-MPER bNAbs 2F5 and 4E10.
In these clinical trials, viremia was initially lowered by conven-
tional ART, and antibodies were added before discontinuing
ART (Mehandru et al., 2007; Trkola et al., 2005). Antibody cock-
tails were unable tomaintain viremic control in all but a very small
number of individuals. As in the humanized mice, resurgent
viremia on antibody therapy was associated with the emergence
of antibody-resistant variants. The viruses emerging during
combination therapy in humans were only resistant to 2G12 sug-
gesting that this may have been the only antibody in the combi-
nation to exert pressure on the virus in humans (Mehandru et al.,
2007; Trkola et al., 2005). The results of the human studies
reinforced the conclusion that antibody therapy would not be
possible for HIV-1 infection due to rapid emergence of resistant
viral variants (Mehandru et al., 2007; Poignard et al., 1999; Trkola
et al., 2005). An important caveat to interpreting these initial
humanized mouse and human therapy experiments is that the
antibodies that were used were far less potent than currently
available reagents.
The possibility that antibodies might be used in therapy was
recently retested using newly available bNAbs in humanized
mice infected with HIV-1YU-2, a difficult to neutralize (tier 2) clade
B strain. When used as single agents, some antibodies
(3BNC117, 10-1074, PGT128, PG16, NIH45-46G54W) but not
others (10E8, 3BC176) induced a small transient drop in viremia
that was associated with the selection of resistant HIV-1YU-2
variants that carried specific mutations in antibody target sites
(Diskin et al., 2013; Horwitz et al., 2013; Klein et al., 2012b;
Malbec et al., 2013). For example, anti-CD4-binding site
antibody NIH45-46G54W (Klein et al., 2012b) selected variants
carrying mutations that altered the CD4-binding site. One of
the notable and unexpected results was that the variants that
escaped from one of the antibodies, 10-1074 (directed at the
Asn332 glycan at the base of V3), were identical in severalCell 156, February 13, 2014 ª2014 Elsevier Inc. 641
independent samples, suggesting that the pathways to escape
this class of antibodies while maintaining viral fitness are limited
(Klein et al., 2012b).
In contrast to earlier experiments with humanized mice, com-
bined antibody therapy with second generation bNAbs led to
sustained viremic suppression to levels below the limit of detec-
tion (Klein et al., 2012b). Most importantly, there was no escape
during a 120 day period or for as long as antibodies remained at
therapeutic concentrations, and in 10%–15% of the mice,
viremia failed to rebound even after antibodies were no longer
detectable (Diskin et al., 2013; Horwitz et al., 2013; Klein et al.,
2012b). Durable control could also be achieved with single anti-
bodies delivered by infusion or by gene therapy using adeno-
associated virus vectors if the initial level of viremia was lowered
with ART (Horwitz et al., 2013). Thus, the ability of a single
antibody to control viremia is directly related to the initial viral
load (Horwitz et al., 2013). In addition to controlling viremia,
antibody therapy also lowered cell-associated viral RNA and
DNA, which are thought to reflect the content of the viral
reservoir (Horwitz et al., 2013). These initial experiments in
humanized mice established the principle that antibodies can
be used to treat HIV-1 and that this type of therapy may impact
the overall size of the viral reservoir.
Many of these initial observations in humanized mice were
confirmed and extended in macaques infected with SHIV, a
chimeric virus that carries a human HIV-1 Env spike and causes
an AIDS-like syndrome (Barouch et al., 2013; Shingai et al.,
2013). Two independent groups of investigators performed anti-
body therapy experiments in macaques that were chronically
infected for a period of 9 months to 3 years with one of two
SHIV strains, SHIVSF162P3 (Barouch et al., 2013), and SHIVAD8
(Shingai et al., 2013). Both viruses can cause an AIDS-like dis-
ease but somemonkeys infected with SF162P3 can resolve their
infections spontaneously (Hsu et al., 2003), whereas those
infected with AD8 invariably died due to loss of CD4 T cells,
lymphoma, and opportunistic infection (Gautam et al., 2012).
Macaques infected with SHIV are far larger than humanized
mice. They carry a greater viral load that is more diverse, and
therefore these animals may represent a greater challenge to
antibody therapy. In contrast to humanized mice that do not
have an intact immune system, macaques, like humans, have
an immune system that actively attempts to control the infection
through both T and B cell responses.
As might be expected from the documented effects of anti-
bodies on viral half-life in macaques (Igarashi et al., 1999), both
studies showed that antibodies rapidly controlled SHIVSF162P3
and SHIVAD8 viremia (Barouch et al., 2013; Shingai et al.,
2013). Like in humanized mice (Horwitz et al., 2013; Klein et al.,
2012b), antibodies decreased cell-associated RNA, and viremia
remained controlled for as long as antibody levels were above
the therapeutic range of 5–10 mg per milliliter for up to 56 days
after infusion (Barouch et al., 2013). Moreover, in both human-
ized mice and macaques, the ability of an antibody to control
infection was directly related to the level of viremia before
initiating therapy (Barouch et al., 2013; Horwitz et al., 2013).
Like in humanized mice, in a small fraction of the SHIVSF162P3-
infected macaques viremia failed to rebound even after the anti-
bodies were cleared (Barouch et al., 2013; Klein et al., 2012b).642 Cell 156, February 13, 2014 ª2014 Elsevier Inc.In contrast to humanized mice, in which single antibodies pro-
ducedonly a small transient drop in viremiawith rapid emergence
of escape variants, amajority of themacaques showed control of
viremia for as long as their antibody concentrations remained
above 1–5 mg/ml (Barouch et al., 2013; Shingai et al., 2013). In
addition, all SHIVSF162P3-infected animals that were retreated
after the initial rebound of viremia responded with a shorter, but
significant suppression of the viral load with no emergence
of characteristic escape mutations (Barouch et al., 2013). The
inability to find previously described escape variants to PGT121
in SF162P3-infected macaques is likely because mutations in
the target site for this antibody failed to produce resistant variants
in SF162P3 (Barouch et al., 2013). This is likely to be a peculiarity
of SHIVSF162P3 since HIVs carrying similar mutations become
resistant to PGT121 and 20%–30% of all HIV-1 strains in large
viral panels including many clade A and C viruses are resistant
to this antibody (Moore et al., 2012;Mouquet et al., 2012a;Walker
et al., 2011a). In the case of SHIVAD8, resistance failed to
emerge in animals during initial treatment with the combination
of 10-1074 and 3BNC117 (5 macaques), or 3BNC117 alone
(2 macaques), but escape variants to 10-1074 were detected
(2 macaques) (Shingai et al., 2013). PGT121 and 10-1074 have
nearly indistinguishable levels of activity when tested against
large standardized panels of HIV-1 strains in TZM-bl assays
(Moore et al., 2012; Mouquet et al., 2012a; Walker et al.,
2011a). However, 10-1074 is more active than PGT121 against
recently obtained clade B transmitted founder viruses (Mouquet
et al., 2012a).Whether these two antibodiesmore generally differ
in their ability to prevent viral escape cannot be determined from
the available macaque experiments because they were per-
formed with two different SHIVs. However, the fact that the two
antibodies are very similar in their breadth and potency on large
viral panels suggests that the observed differences are related
to the specific SHIVs being tested and may be anecdotal.
Why SHIV infection in macaques appears to be easier to
control than HIV-1 infection in humanized mice and whether
the human infection will be similar to the mouse or monkey is
not known. The differences between the two species could be
due to existing antiviral immune responses in the macaques,
differences betweenHIV-1 and SHIV, or other factors that remain
to be determined. SHIV infection in macaques resembles HIV-1
infection in humans in that initial infection is accompanied by
high levels of viremia that decrease by 1–2 logs to a set-point
that is maintained for long periods of time before the develop-
ment of AIDS. The set point is established and then maintained
by immune pressure that is imposed predominantly by cytotoxic
T cells, and perhaps by antibodies that select resistant viral
variants (Huang et al., 2010; Simon et al., 2006; Walker and
McMichael, 2012). Although the immune response is unable to
control HIV-1 infection in macaques, it is possible that it contrib-
utes to and enhances the effects of the passively administered
antibodies making escape more difficult in macaques than in
the humanized mice that lack these responses. A second possi-
bility is that the human Env protein has fewer degrees of freedom
to escape from bNAbs and still retain the ability to infect
macaque cells (versus human cells). In support of this idea,
only a limited number of Envs can be used to produce SHIVs.
Thus, it may be more difficult for the human Env to produce a
CD4-binding site escape (to an anti-CD4-binding site antibody)
that still binds to macaque CD4 than for the same Env to escape
the antibody and retain binding to the autologous human CD4.
Understanding why it is easier to control viremia in macaques
than in humanized mice will be interesting and is likely to impact
on therapeutic strategies. But irrespective of the mechanism,
the extensive clinical experience with antiretroviral drugs, and
the fact that no single antibody covers all HIV-1 variants, sug-
gests that combinations of antibodies will be required to control
viremia in humans.
Perspectives for Antibody-Based Vaccines and Therapy
Antibodies can prevent HIV-1 infection in mice and chimpan-
zees, and SHIV infection in macaques (Balazs et al., 2012; Bar-
ouch et al., 2013; Gruell et al., 2013; Prince et al., 1991; Safrit
et al., 1993; Shingai et al., 2013), but attempts to produce effec-
tive HIV-1 vaccines by eliciting neutralizing antibodies have been
disappointing to date (McCoy and Weiss, 2013). However, the
vaccine strategies that were tested did not take into account
the recent discovery of naturally arising broad and potent
anti-HIV neutralizing antibodies. A key observation is that devel-
opment of broadly neutralizing antibodies requires extensive
somatic mutation (Klein et al., 2013a), which is likely to occur
as a result of iterative rounds of germinal center selection (Klein
et al., 2013a; Klein et al., 2013b). By longitudinal tracking of the
coevolving Env antigen and a clone of broadly neutralizing anti-
bodies, Liao and colleagues illustrated how breadth and poly-
reactivity may develop (Liao et al., 2013). The germline ancestor
of the CH103 lineage bound to the donor’s transmitted/founder
Env, and reactivity to the evolving virus developed over time by
somatic hypermutation, thereby increasing the potency and
breadth of the antibody. Similarly, longitudinal studies by Moore
and colleagues revealed how viral evolution in response to anti-
body pressure exposes additional targets that can elicit bNAbs
(Moore et al., 2012; Wibmer et al., 2013). This type of naturally
occurring antibody evolution arises as a result of exposure
to a series of mutant Env variants over time. Incorporating this
concept into vaccine strategies would be a significant departure
from current vaccines that typically involve immunization and
boosting with a monomorphic antigen.
Antibody cloning also revealed that most humans that develop
serologic breadth and potency do so by producing antibodies to
more than one site of vulnerability. Moreover, it uncovered
a series of targets on Env that are vulnerable to broad and potent
antibodies. With a growing understanding of the structural
underpinnings of antibody-mediated neutralization, it may
become possible to design antigens that recruit antibodies
targeted specifically to these regions in Env (Jardine et al., 2013).
Despite recent advances, an effective antibody-based HIV-1
vaccine is still on the distant horizon in part because there are
as yet no successful preclinical demonstrations of how to elicit
broad and potent anti-HIV-1 antibodies. Moreover, any new
vaccine concept is very time consuming to test in humans. In
contrast, preclinical experiments in humanized mice and
macaques strongly support testing antibody therapies for
HIV-1 in humans in the near term.
Since ART is less expensive, and easier to administer, than
antibody therapy, passive immunotherapy will have to comple-ment existing therapies in unique and clinically significant ways
before it can considered for clinical use. In addition, there are a
number of important questions that will need to be addressed
to evaluate whether there is any role of antibodies as therapeu-
tics in the anti-HIV armamentarium. First and foremost, it will
be essential to determine whether single antibodies or combina-
tions of antibodies are safe and can impact the level of circu-
lating viremia and/or cell-associated viral reservoirs in infected
humans. Antibody and ART combinations should be tested for
the possibility that antibodies can further decrease viremia
in ART-treated individuals with detectable viral loads. Finally,
because antibodies have the potential to clear infected cells it
will be important to begin to think about the role of antibodies
in attempts to develop a cure for HIV-1.
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